SUMMARY We started to study on the development of EPA ethyl ester(EPA-E) for a drug in co-operation with doctors and pharmaceutical companies in 1979, and we were permitted to manufacture the drug for atherosclerosis obliterans named EPADEL in 1990. In this work, several methods were examined to purify EPA-E in fish oil ethyl ester mixture to pharmaceutical grade, and the distillation with mufti-tower system and cyclic process of urea adduction method were developed. By the combination of above two processes, 90% EPA-E was obtained from fish oil ethyl ester containing 18% EPA. Stability tests revealed that EPA-E in a closed container could be stored without any undesirable changes at room temperature for 2 years. Clinical studies clarified the effect of EPA-E on both atherosclerosis obliterans and hyperlipidemia.
shows the major fatty acid composition of 4 kinds of fish oil 3) commercially available. As for EPA content, highest value was observed in sardine oil. Another important factor is the composition among C20 group, the content of C20 monoenes was relatively low in sardine, and especially the ratio of tetraenoic acids to EPA was lowest in sardine.
Consequently we selected sardine oil as a material of EPA-E. production of pure EPA-E, and concluded that the combination process of distillation and urea adduct separation in order was effective. Fig.1 shows the flow diagram of the process. To solve these problems , the system equipped with 4 towers was developed as illustrated in Fig.2 . Esters of acids less than C20 were distilled from the top of the second tower, and esters of acids larger than C20 were drawn from the bottom of the third tower, then esters of C20 acid involving EPA-E were recovered from the top of the fourth tower as main fraction. Table 2 Comparison between 2 towers distillation and 4 towers distillation Efficiency of 4 towers system was compared with 2 towers system in Table 2 . Though the light fraction of 2 towers system contained 5.7% EPA, that of 4 towers system was only 0.8%. As for main fraction, 9.3% of low molecular esters and 1.6% of C18:4, which could not be separated from EPA by urea treatment, were remained in two towers system. In contrast, the main fraction of 4 towers system consisted of nearly 100% C20 and C18:4
was not detected. In addition, the improvement of the resolution brought 60% increase of EPA recovery.
Urea adduct separation
Main fraction obtained by distillation was applied to urea adduct separation. Fig.3 shows the conventional batch process. Ester of C20 acids was mixed with urea/methanol Urea adduct in methanol was heated to decompose, lower unsaturated esters released were extracted with hexane.
And remaining methanol solution of urea was recycled.
The advantages of this process are no loss of urea and methanol, and easiness to make the system closed to avoid the oxidation of EPA-E in the treatment.
Change in fatty acid composition in our combination process of distillation and urea adduct separation is shown in Table 3 . EPA contained 18% in material oil was concentrated to over 80% only by the distillation with 4 towers system, and after removal of lower unsaturated esters such as C20 monoenes by urea adduct separation,
EPA-E of 92% purity was obtained.
This process was confirmed to be applicable to the purification of docosahexaenoic acid ethyl ester using tuna oil as a material. No significant change was observed except acid value which revealed slight but constant increase in the range lower than 0.1. From these observations it was concluded that EPA-E could be stored without any undesirable changes in a closed container at room temperature for at least 2 years.
RESULTS

OF CLINICAL STUDIES
Effects of EPA-E on chronic arterial occlusion 6) and hyperlipidemia 7) were evaluated by clinical studies,
Changes in the size of ischemic ulcer of the patients suffered from atherosclerosis obliterans were illustrated in Significant and linear reduction in the size of ulcer was observed by the treatment with 1800mg/day of EPA-E . Fig. 7 shows the changes in total cholesterol (T Ch), low density lipoprotein cholesterol(LDL-C), triglyceride(TG) and high density lipoprotein cholesterol(HDL-C) in serum of hyperlipidemic patients administered 2700mg/day of EPA-E for 16 weeks . Five % reduction in T-Ch , 4% reduction of LDL-C, 13% reduction of TG and 1% increase of HDL-C were observed.
CONCLUSION
To develop EPA-E for a drug , we investigated the process to produce 90% EPA -E in commercial scale, and the combined process of continuous 4 towers distillation system and cyclic urea adduct separation system was established. Stability test demonstrated that EPA-E could be stored without any undesirable changes in closed container at room temperature for at least 2 years. Effect of EPA-E was confirmed by clinical studies on atherosclerosis obliterans patients and hyperlipidemic patients dosed 1800mg/day and 2700mg/day, respectively.
